This exploratory study is designed to compare safety and efficacy between a Tegoprazan dose-specific standard triple therapy and Lansoprazole standard triple therapy in H. pylori positive patients.

A Randomized, Double-Blind, Active-controlled, Multicenter, Therapeutic Exploratory Study to to Evaluate the Safety and Efficacy of a Standard Triple Therapy with Tegoprazan and Lansoprazole standard triple therapy in H. pylori Positive Patients, twice a day for 14 days.

Inclusion Criteria:

• H. pylori positive at screening
• Subjects who have upper gastrointestinal disease

Exclusion Criteria:

• Having received prior therapy for eradication of H. pylori
• Prior use of P-CAB, proton pump inhibitors (PPIs), H2 receptor blockers within 14 days
• Prior use of H. pylori eradication effective antibiotics, bismuth within 28 days